The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever. In ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Hims & Hers is pushing a cheaper ... The early-rate deadline for Fast Company’s Innovation by Design Awards is Friday, March 21, at 11:59 p.m. PT. Apply today.

Over the last 12 months, HIMS has generated $101 million in net income. Yet having come so far so fast, Hims & Hers has attracted its fair share of short-sellers. HIMS has 210.1 million shares ...

The two remained cautious about the company's prospects, however, as they held fast to their equivalents of hold recommendations. The optimism is understandable, as Hims & Hers is an innovative ...

HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever. In this video ...

However, given how fast revenue is growing and its positive free cash flow, Hims & Hers seems to be getting a good return on this marketing spend. So what's the problem? Why is the stock down?

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its weight loss drug program. It is guiding for margin expansion and fast ...